Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 shares of common stock of the Company originally issued in March 2025, at their current exercise price of $3.75 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-286346). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.2 million, before deducting financial advisory fees.